Everyone with narcolepsy knows that, as things stand, there is no cure for the condition. Instead, we rely on medication to control the symptoms, though for many people those drugs do not work well enough or have adverse side-effects. So what does the future hold? Will there be new and more effective treatments? What are scientists around the world working on to help us?
This research programme is investigating school performance and well-being in children with narcolepsy aged 8-16 years old. The project has been set up by The University of Leeds and has received ethical approval from the School of Psychology's Research Ethics Committee (ref: 15-0198, date: 03.08.15). The research is taking place in the United Kingdom and in the Republic of Ireland.
Flamel (Part of the Avadel Pharmaceuticals), are looking for subjects to participate in their clinical trial evaluating their once nightly sodium oxybate for the treatment of EDS and cataplexy in narcolepsy.
FT218 is dosed once at bedtime unlike the currently marketed formulation of sodium oxybate (Xyrem®) which needs to be taken twice nightly, once at bedtime and then again 2.5 – 4 hours later.
Patients with a diagnosis of narcolepsy who meet the study criteria may be eligible to participate in our clinical trial.
Aimed at tackling the challenges and discrimination faced by the narcolepsy community across the UK, the Narcolepsy Charter is a written statement of the rights of people with narcolepsy and their carers. It sets out the basic rights that people with narcolepsy and their carers deserve and should expect.